24-012262 niaaa requires the filing of a national stage application in europe in order to pursue rights in "cannabinoid receptor modulating compounds" as described in NIH reference #…
Ended Awarded Last action
- Contract number
- 75N92024F00002
- Awardee
-
Klarquist Sparkman, LLP UEI C75KZNSK3CL4
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,910
Award facts
- Opportunity
-
- 20KSCHM010624 Solicitation number
- Contract value 100% obligated
- $11,910.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute on Alcohol Abuse and Alcoholism National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541110 Offices of Lawyers
- PSC
- R418 Support- Professional: Legal
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Portland, OR 97204, USA
Award details come from SAM.gov/FPDS.
About this award
This federal contract award is a $11,910 firm fixed-price delivery order to Klarquist Sparkman, LLP, an intellectual property law firm specializing in patent, trademark, and copyright services for federal agencies. The contract is to file a national stage patent application in Europe for "Cannabinoid Receptor Modulating Compounds" on behalf of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS).
The contract is part of the NIH Patent Legal Services IDIQ contract, a $115 million multiple-award IDIQ covering biotechnology, chemistry, medical engineering, and software patent services for various NIH institutes and the Centers for Disease Control and Prevention (CDC). Klarquist Sparkman also holds a $5 million single-award IDIQ with the Food and Drug Administration (FDA) for comprehensive patent legal support. These contracts demonstrate Klarquist Sparkman's deep expertise in intellectual property law and its significant role in supporting the government's medical research and public health initiatives.
Description
24-012262 niaaa requires the filing of a national stage application in europe in order to pursue rights in "cannabinoid receptor modulating compounds" as described in NIH reference # e-189-2021-0-EP-01.
Quick answers
Who was awarded contract 75N92024F00002?
75N92024F00002 was awarded to Klarquist Sparkman, LLP by National Heart Lung and Blood Institute (National Institutes of Health) on June 5, 2024.
How much is contract 75N92024F00002 worth?
The government has obligated $11,910 on 75N92024F00002.
Which agency awarded contract 75N92024F00002?
National Heart Lung and Blood Institute (National Institutes of Health) awarded 75N92024F00002, with funding from National Institute on Alcohol Abuse and Alcoholism (National Institutes of Health).
Is contract 75N92024F00002 an order under another contract?
Yes. 75N92024F00002 is a delivery order under 75N98020D00052, an indefinite delivery contract, on NIH Patent Legal Services.
Was contract 75N92024F00002 competed?
The extent of competition for 75N92024F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award